![](https://monteverdelaw.com/wp-content/uploads/case-logo/satsuma-pharmaceuticals-inc.png)
Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), relating to its proposed sale to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, STSA Shareholders are expected to receive one non-tradeable CVR of up to $5.77 in cash plus $0.91 in cash per share they own.